EUDA Health Holdings Limited announced on August 26, 2025, that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has secured exclusive worldwide distribution rights for a next-generation immune health supplement. The supplement is from Chemokine Pte. Ltd., a Singapore-based biotech company specializing in immune health.
This agreement expands EUDA's wellness product portfolio, reinforcing its commitment to non-invasive and preventive healthcare solutions. The new supplement is designed to cater to the growing demand for science-backed immunity and longevity products in Asia.
The acquisition of these distribution rights is a strategic move to enhance EUDA's offerings and strengthen its position in the rapidly expanding longevity sector. This initiative directly complements the company's broader strategy to transform health and wellness in Asia.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.